Highlights•The CD19 paradigm has established CARs as a novel immunotherapy in
oncology.•The synthetic tool box is not limited to CARs and includes CCRs, iCARs and …

Chimeric antigen receptors: driving immunology towards synthetic biology | CiNii Research
CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索フォームへ移動 論文・データを …

The advent of second generation CARs and the CD19 paradigm have ushered a new
therapeutic modality in oncology. In contrast to earlier forms of adoptive cell therapy, which …

The advent of second generation chimeric antigen receptors and the CD19 paradigm have
ushered a new therapeutic modality in oncology. In contrast to earlier forms of adoptive cell …

The advent of second generation CARs and the CD19 paradigm have ushered a new
therapeutic modality in oncology. In contrast to earlier forms of adoptive cell therapy, which …

The advent of second generation chimeric antigen receptors and the CD19 paradigm have
ushered a new therapeutic modality in oncology. In contrast to earlier forms of adoptive cell …